Preoperative Comorbidity Correlates Inversely with Survival after Intestinal and Multivisceral Transplantation in Adults

Table 4

Peri- and postoperative data.

Variables	Results
Induction agents (%)
Corticosteroids	13.90%
Daclizumab (Zenapax)	16.66%
Alemtuzumab (Campath)	69.44%
Number of rejection episodes (mean ± SD)	1.22 ± 1.34
Severity of rejection episodes per patient; (mean ± SD)
Mild	1.419 ± 0.662
Moderate	0.391 ± 0.718
Severe	0.318 ± 0.547
Rejection-free period (days) (mean ± SD)	357.63 ± 21.54
Posttransplant hospital stay (days) (mean ± SD)	60.69 ± 45.57